ACADIA Pharmaceuticals/$ACAD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Ticker
$ACAD
Sector
Primary listing
Employees
797
Headquarters
Website
ACAD Metrics
BasicAdvanced
$3.6bn
9.68
$2.20
0.86
-
Price and volume
Market cap
$3.6bn
Beta
0.86
52-week high
$28.35
52-week low
$19.69
Average daily volume
1.8m
Financial strength
Current ratio
3.587
Quick ratio
3.273
Long term debt to equity
3.125
Total debt to equity
3.125
Profitability
EBITDA (TTM)
92.707
Gross margin (TTM)
61.58%
Net profit margin (TTM)
34.30%
Operating margin (TTM)
7.39%
Effective tax rate (TTM)
-226.35%
Revenue per employee (TTM)
$1,370,000
Management effectiveness
Return on assets (TTM)
3.69%
Return on equity (TTM)
37.32%
Valuation
Price to earnings (TTM)
9.683
Price to revenue (TTM)
3.286
Price to book
2.9
Price to tangible book (TTM)
3.19
Price to free cash flow (TTM)
16.942
Free cash flow yield (TTM)
5.90%
Free cash flow per share (TTM)
1.255
Growth
Revenue change (TTM)
9.93%
Earnings per share change (TTM)
60.43%
3-year revenue growth (CAGR)
28.17%
10-year revenue growth (CAGR)
166.33%
3-year earnings per share growth (CAGR)
34.11%
10-year earnings per share growth (CAGR)
2.71%
What the Analysts think about ACAD
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
ACAD Financial Performance
Revenues and expenses
ACAD Earnings Performance
Company profitability
ACAD News
AllArticlesVideos
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth
MarketBeat·1 week ago
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
MarketBeat·2 weeks ago
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs